针对多形性胶质母细胞瘤的表皮生长因子受体III型变异体（EGFRvIII）
Targeting EGFRvIII for glioblastoma multiforme.
作者信息
Yang Ju, Yan Jing, Liu Baorui
机构信息
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing 210008, China.
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing 210008, China.
出版信息
Cancer Lett. 2017 Sep 10;403:224-230. doi: 10.1016/j.canlet.2017.06.024. Epub 2017 Jun 23.
Glioblastoma multiforme (GBM) is the most progressive primary brain tumor. Targeting a novel and highly specific tumor antigen is one of the strategies to overcome tumors. EGFR variant III (EGFRvIII) is present in 25%-33% of all patients with GBM and is exclusively expressed on tumor tissue cells. Currently, there are various approaches to target EGFRvIII, including CAR T-cell therapy, therapeutic vaccines, antibodies, and Bi-specific T Cell Engager. In this review, we focus on the preclinical and clinical findings of targeting EGFRvIII for GBM.
多形性胶质母细胞瘤（GBM）是最具侵袭性的原发性脑肿瘤。靶向一种新型且高度特异性的肿瘤抗原是克服肿瘤的策略之一。表皮生长因子受体III型变异体（EGFRvIII）存在于25%-33%的GBM患者中，且仅在肿瘤组织细胞上表达。目前，有多种靶向EGFRvIII的方法，包括嵌合抗原受体（CAR）T细胞疗法、治疗性疫苗、抗体和双特异性T细胞衔接器。在本综述中，我们聚焦于针对GBM靶向EGFRvIII的临床前和临床研究结果。
Zotero 插件